HENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List

Stock News12-07 18:44

HENGRUI PHARMA (01276) announced that several of its products have been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security.

Through price negotiations, the following drugs were newly added to the NRDL: - Trastuzumab Emtansine for Injection - Famitinib Malate Capsules - Funazumab Injection - Emavansertib Sulfate Tablets - Fosnetupitant and Palonosetron for Injection - Recaticimab for Injection - Abiraterone Acetate Tablets (II) - Irinotecan Hydrochloride Liposome Injection (II) - Retagliptin and Metformin Tablets (I)/(II) - Perfluorohexyloctane Eye Drops

Additionally, the following drugs had new indications successfully included: - Camrelizumab for Injection - Fluzoparib Capsules - Fumarate Tegileridine Injection

The following drugs were successfully renewed in the NRDL: - Pyrotinib Maleate Tablets - Hetrombopag Ethanolamine Tablets - Retagliptin Phosphate Tablets - Remimazolam Tosilate for Injection - Pegfilgrastim Sulfate Injection

Furthermore, Apatinib Mesylate Tablets and Bupivacaine Liposome Injection were adjusted to the conventional NRDL with new indications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128895116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128895116","market":"nz","top_or_hot":-1,"title":"HENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List","media":"Stock News","content":"<p>HENGRUI PHARMA (01276) announced that several of its products have been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security.</p>\n<p>Through price negotiations, the following drugs were newly added to the NRDL:  \n- Trastuzumab Emtansine for Injection  \n- Famitinib Malate Capsules  \n- Funazumab Injection  \n- Emavansertib Sulfate Tablets  \n- Fosnetupitant and Palonosetron for Injection  \n- Recaticimab for Injection  \n- Abiraterone Acetate Tablets (II)  \n- Irinotecan Hydrochloride Liposome Injection (II)  \n- Retagliptin and Metformin Tablets (I)/(II)  \n- Perfluorohexyloctane Eye Drops</p>\n<p>Additionally, the following drugs had new indications successfully included:  \n- Camrelizumab for Injection  \n- Fluzoparib Capsules  \n- Fumarate Tegileridine Injection</p>\n<p>The following drugs were successfully renewed in the NRDL:  \n- Pyrotinib Maleate Tablets  \n- Hetrombopag Ethanolamine Tablets  \n- Retagliptin Phosphate Tablets  \n- Remimazolam Tosilate for Injection  \n- Pegfilgrastim Sulfate Injection</p>\n<p>Furthermore, Apatinib Mesylate Tablets and Bupivacaine Liposome Injection were adjusted to the conventional NRDL with new indications.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (01276) announced that several of its products have been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security.</p>\n<p>Through price negotiations, the following drugs were newly added to the NRDL:  \n- Trastuzumab Emtansine for Injection  \n- Famitinib Malate Capsules  \n- Funazumab Injection  \n- Emavansertib Sulfate Tablets  \n- Fosnetupitant and Palonosetron for Injection  \n- Recaticimab for Injection  \n- Abiraterone Acetate Tablets (II)  \n- Irinotecan Hydrochloride Liposome Injection (II)  \n- Retagliptin and Metformin Tablets (I)/(II)  \n- Perfluorohexyloctane Eye Drops</p>\n<p>Additionally, the following drugs had new indications successfully included:  \n- Camrelizumab for Injection  \n- Fluzoparib Capsules  \n- Fumarate Tegileridine Injection</p>\n<p>The following drugs were successfully renewed in the NRDL:  \n- Pyrotinib Maleate Tablets  \n- Hetrombopag Ethanolamine Tablets  \n- Retagliptin Phosphate Tablets  \n- Remimazolam Tosilate for Injection  \n- Pegfilgrastim Sulfate Injection</p>\n<p>Furthermore, Apatinib Mesylate Tablets and Bupivacaine Liposome Injection were adjusted to the conventional NRDL with new indications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828631.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC","start_time":0,"source_url":"","article_id":"1128895116","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128895116","pubTimestamp":1765104257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) announced that several of its products have been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0060":"抗癌","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0196":"行业龙头","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","01276":"恒瑞医药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0239":"医药制造","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","BK0183":"MSCI概念","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","BK0188":"融资融券","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0012":"证金概念","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0028":"国家队","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1191":"制药"},"translate_title":"恒瑞医药(01276)多款药品纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA (01276) announced that several of its products have been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security.\nThrough price negotiations, the following drugs were newly added to the NRDL:  \n- Trastuzumab Emtansine for Injection  \n- Famitinib Malate Capsules  \n- Funazumab Injection  \n- Emavansertib Sulfate Tablets  \n- Fosnetupitant and Palonosetron for Injection  \n- Recaticimab for Injection  \n- Abiraterone Acetate Tablets (II)  \n- Irinotecan Hydrochloride Liposome Injection (II)  \n- Retagliptin and Metformin Tablets (I)/(II)  \n- Perfluorohexyloctane Eye Drops\nAdditionally, the following drugs had new indications successfully included:  \n- Camrelizumab for Injection  \n- Fluzoparib Capsules  \n- Fumarate Tegileridine Injection\nThe following drugs were successfully renewed in the NRDL:  \n- Pyrotinib Maleate Tablets  \n- Hetrombopag Ethanolamine Tablets  \n- Retagliptin Phosphate Tablets  \n- Remimazolam Tosilate for Injection  \n- Pegfilgrastim Sulfate Injection\nFurthermore, Apatinib Mesylate Tablets and Bupivacaine Liposome Injection were adjusted to the conventional NRDL with new indications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128895116","isCrawlerRequest":true}